异动解读 | 再鼎医药盘中大涨6.63%，RTW Fund Group增持近600万股

异动解读

Jun 04, 2025

再鼎医药（09688.HK）今日盘中大涨6.63%，引起市场广泛关注。截至发稿，该股报25.400港元/股，成交量157.39万股，换手率0.14%，振幅4.55%。资金方面，该股资金流入2448.77万港元，流出937.687万港元。

本次股价上涨主要受到大股东增持的利好消息推动。根据香港联交所6月3日披露的文件，RTW Fund Group GP, LLC于5月27日以每股均价3.099美元增持再鼎医药591.43万股普通股股份，价值约1,832.83万美元。增持后，RTW Fund Group GP, LLC最新持股数目为5,610.11万股股份，好仓比例由4.55%升至5.08%。这一举动显示了大股东对公司未来发展的信心，刺激了投资者的买入热情。

再鼎医药有限公司是一家主要从事生物制药的控股公司，致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。公司拥有从发现阶段到临床项目后期的一系列专利候选药物，包括"则乐"、"OPTUNE"、"擎乐"、"纽再乐"及"卫伟迦"等。最近的财报数据显示，该公司实现营业收入8.28亿港元，净利润-3.77亿港元，每股收益-0.31港元，毛利5.28亿港元，市盈率-14.04倍。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1108780368"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1108780368\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1108780368?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-06-04 09:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108780368","market":"nz","top_or_hot":-1,"title":"异动解读 | 再鼎医药盘中大涨6.63%，RTW Fund Group增持近600万股","media":"异动解读","content":"<p>再鼎医药（09688.HK）今日盘中大涨6.63%，引起市场广泛关注。截至发稿，该股报25.400港元/股，成交量157.39万股，换手率0.14%，振幅4.55%。资金方面，该股资金流入2448.77万港元，流出937.687万港元。</p>\n\n<p>本次股价上涨主要受到大股东增持的利好消息推动。根据香港联交所6月3日披露的文件，RTW Fund Group GP, LLC于5月27日以每股均价3.099美元增持再鼎医药591.43万股普通股股份，价值约1,832.83万美元。增持后，RTW Fund Group GP, LLC最新持股数目为5,610.11万股股份，好仓比例由4.55%升至5.08%。这一举动显示了大股东对公司未来发展的信心，刺激了投资者的买入热情。</p>\n\n<p>再鼎医药有限公司是一家主要从事生物制药的控股公司，致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。公司拥有从发现阶段到临床项目后期的一系列专利候选药物，包括\"则乐\"、\"OPTUNE\"、\"擎乐\"、\"纽再乐\"及\"卫伟迦\"等。最近的财报数据显示，该公司实现营业收入8.28亿港元，净利润-3.77亿港元，每股收益-0.31港元，毛利5.28亿港元，市盈率-14.04倍。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 再鼎医药盘中大涨6.63%，RTW Fund Group增持近600万股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 再鼎医药盘中大涨6.63%，RTW Fund Group增持近600万股\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-06-04 09:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>再鼎医药（09688.HK）今日盘中大涨6.63%，引起市场广泛关注。截至发稿，该股报25.400港元/股，成交量157.39万股，换手率0.14%，振幅4.55%。资金方面，该股资金流入2448.77万港元，流出937.687万港元。</p>\n\n<p>本次股价上涨主要受到大股东增持的利好消息推动。根据香港联交所6月3日披露的文件，RTW Fund Group GP, LLC于5月27日以每股均价3.099美元增持再鼎医药591.43万股普通股股份，价值约1,832.83万美元。增持后，RTW Fund Group GP, LLC最新持股数目为5,610.11万股股份，好仓比例由4.55%升至5.08%。这一举动显示了大股东对公司未来发展的信心，刺激了投资者的买入热情。</p>\n\n<p>再鼎医药有限公司是一家主要从事生物制药的控股公司，致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。公司拥有从发现阶段到临床项目后期的一系列专利候选药物，包括\"则乐\"、\"OPTUNE\"、\"擎乐\"、\"纽再乐\"及\"卫伟迦\"等。最近的财报数据显示，该公司实现营业收入8.28亿港元，净利润-3.77亿港元，每股收益-0.31港元，毛利5.28亿港元，市盈率-14.04倍。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1108780368","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108780368","pubTimestamp":1749001495,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"再鼎医药今日盘中大涨6.63%，引起市场广泛关注。截至发稿，该股报25.400港元/股，成交量157.39万股，换手率0.14%，振幅4.55%。资金方面，该股资金流入2448.77万港元，流出937.687万港元。本次股价上涨主要受到大股东增持的利好消息推动。根据香港联交所6月3日披露的文件，RTW Fund Group GP, LLC于5月27日以每股均价3.099美元增持再鼎医药591.43万股普通股股份，价值约1,832.83万美元。增持后，RTW Fund Group GP, LLC最新持股数目为5,610.11万股股份，好仓比例由4.55%升至5.08%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09688":"再鼎医药"},"translate_title":"Interpretation of the change: Zai Lab rose 6.63% during the session, and RTW Fund Group increased its holdings by nearly 6 million shares","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"再鼎医药（09688.HK）今日盘中大涨6.63%，引起市场广泛关注。截至发稿，该股报25.400港元/股，成交量157.39万股，换手率0.14%，振幅4.55%。资金方面，该股资金流入2448.77万港元，流出937.687万港元。\n本次股价上涨主要受到大股东增持的利好消息推动。根据香港联交所6月3日披露的文件，RTW Fund Group GP, LLC于5月27日以每股均价3.099美元增持再鼎医药591.43万股普通股股份，价值约1,832.83万美元。增持后，RTW Fund Group GP, LLC最新持股数目为5,610.11万股股份，好仓比例由4.55%升至5.08%。这一举动显示了大股东对公司未来发展的信心，刺激了投资者的买入热情。\n再鼎医药有限公司是一家主要从事生物制药的控股公司，致力于通过产品的发现、开发和商业化解决肿瘤、自身免疫疾病、感染性疾病和中枢神经系统疾病领域未被满足的医疗需求。公司拥有从发现阶段到临床项目后期的一系列专利候选药物，包括\"则乐\"、\"OPTUNE\"、\"擎乐\"、\"纽再乐\"及\"卫伟迦\"等。最近的财报数据显示，该公司实现营业收入8.28亿港元，净利润-3.77亿港元，每股收益-0.31港元，毛利5.28亿港元，市盈率-14.04倍。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}